During the past decade, NYU Langone Ambulatory Care Brooklyn Heights conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 3 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 3 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NYU Langone Ambulatory Care Brooklyn Heights" #1 sponsor was "Bristol-Myers Squibb" with 3 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Pfizer" with 2 trials sponsored, "R-Pharm International, LLC" with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NYU Langone Ambulatory Care Brooklyn Heights" #1 collaborator was "OCT Clinical Trials" with 2 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "Quintiles, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "NYU Langone Ambulatory Care Brooklyn Heights" are "Rheumatoid Arthritis" (6 trials), "Systemic Lupus Erythematosus" (4 trials), "Arthritis, Psoriatic" (2 trials), "Lupus Nephritis" (2 trials) and "Arthritis" (1 trials). Many other conditions were trialed in "NYU Langone Ambulatory Care Brooklyn Heights" in a lesser frequency.

Most popular intervention types in "NYU Langone Ambulatory Care Brooklyn Heights" are "Drug" (14 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Guselkumab" (2 trials), "Abatacept" (1 trials), "Adalimumab" (1 trials) and "Adalimumab 40mg q2w" (1 trials). Other intervention names were less common.

The vast majority of trials in "NYU Langone Ambulatory Care Brooklyn Heights" are 15 trials for "All" genders.

Currently, there are NaN active trials in "NYU Langone Ambulatory Care Brooklyn Heights". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in NYU Langone Ambulatory Care Brooklyn Heights, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in NYU Langone Ambulatory Care Brooklyn Heights, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".